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Abstract Several analogues of diaminopimelic acid (A2pm) 
were tested as substrates or inhibitors of the meso-diaminopimel- 
ate-adding enzyme from Escherichia coll. They included 
lanthionine derivatives, a phosphonic analogue, heterocyclic 
compounds, 3-fiuoro-A2pm, 4-methylene-A2pm and N-hydroxy- 
A2pm. The best substrates were, in decreasing order of specific 
enzyme activity, (2S,3R,6S)-3-fluoro-A2pm, meso-lanthioulne 
sulfoxide and N-hydroxy-A2pm (mixture of stereoisomers). In 
those cases where all the stereoisomers were available, the 
specificity could be described as meso >> DD = LL. N-Hydroxy- 
A2pm (mixture of stereoisomers) trongly inhibited the addition 
of radioactive meso-A2pm to UDP-N-acetylmuramoyl-dipeptide. 
Key words: meso-Diaminopimelate-adding enzyme; 
Diaminopimelic acid analog; MurE; Peptidoglycan 
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1. Introduction 
Diaminopimelic acid (A2pm, compound 1; Fig. 1) is in- 
volved in two essential anabolic pathways of bacteria: protein 
and peptidoglycan biosyntheses (Fig. 2). In all eubacteria nd 
in higher plants the LL isomer of A2pm is synthesized from 
aspartic acid in several steps. It is then converted by epimerase 
DapF into the meso isomer, which is decarboxylated into L- 
lysine by decarboxylase LysA [1]. In some bacterial species a 
dehydrogenase directly converts tetrahydrodipicolinic a id 
into meso-A2pm (Fig. 2). A2pm is introduced into the pepti- 
doglycan pathway by its addition to UDP-MurNAc-dipeptide 
to yield UDP-MurNAc-tripeptide. This step is catalyzed by 
the A2pm-adding enzyme MurE [2]. 
Since mammals lack the A2pm pathway, specific inhibitors 
of the enzymes along this route are potential antibacterial 
agents. There has been growing interest in the design and 
synthesis of A2pm analogues, some of which have been as- 
sayed either for antibacterial ctivity (see [3] for a recent ex- 
ample) or for a specific effect on the epimerase [4-9], the 
decarboxylase [9-11], the dehydrogenase [5,8,9] or less fre- 
quently the A2pm-adding enzyme [12-15]. Herein we take 
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advantage of the availability of several previously synthesized 
A2pm analogues (Fig. 1) to assay them as substrates or in- 
hibitors of MurE from Escherichia coli. 
2. Materials and methods 
2.1. Chemicals 
UDP-MurNAc-L-Ala-D-Glu [16], UDP-MurNAc-L-Ala-D-[14C]Glu 
[17] and meso-A2pm [18] were obtained according to published 
procedures, meso-[laC]A2pm (11.6 TBq mo1-1) was purchased from 
CEA (Saclay, France). The synthesis of A2pm analogues 2-8 and 10 
has already been described [5,6,8,9,11]; analogue 9 was synthesized 
according to the procedure of Girodeau et al. [10]. The MurE activity 
was partially purified from E. coli JM83(pHE5) as described pre- 
viously [13]. 
2.2. Assays of analogues as substrates 
The analogues of Azpm were tested for their addition to UDP- 
MurNAc-L-Ala-t)-[laC]Glu in a mixture (final volume: 50 ktl) contain- 
ing 0.1 M Tris-HC1, pH 8.6, 0.1 M MgCI2, 5 mM ATP, 0.1 mM 
UDP-MurNAc-L-Ala-D-[14C]GIu (0.9 kBq), 10 mM meso-A2pm or 
analogue, and enzyme (0.794.3 Ixg of protein dissolved in 15 ].tl of 
20 mM potassium phosphate, 1 mM 2-mercaptoethanol, 0.1 mM 
MgCI2, pH 7.0). After 30 or 60 min at 37°C, the reaction was stopped 
by addition of 10 ~tl of glacial acetic acid. The amounts of product 
and unreacted UDP-MurNAc-dipeptide were then determined by 
high-voltage electrophoresis (pH 1.9, 40 V cm -~, 2 h), autoradiogra- 
phy and scintillation counting. For Kr~ determinations, the concentra- 
tion of UDP-MurNAc-dipeptide was 0.2 mM and those of the amino 
acids were 1 15 mM for 3a, 0.2-7.5 mM for 8 and 0.5-10 mM for 10; 
values + standard eviations at 95% of confidence were calculated 
from the fitted regression equations [19] using the v vs. v/[S] plot. 
2.3. Assays of analogues as inhibitors 
The analogues of A2pm were tested for their ability to inhibit the 
addition of meso-[~4C]A2pm to UDP-MurNAc-dipeptide in a mixture 
(final volume: 50 ktl) containing 0.1 M Tris-HC1, pH 8.6, 0.1 M 
MgC12, 5 mM ATP, 1 mM UDP-MurNAc-dipeptide, 10 ~tM meso- 
[14C]A2pm (0.9 kBq), 5 mM analogue, and enzyme (0.63 Isg of protein 
dissolved in 15 ~tl of the same buffer as in Section 2.2). After 20 rain at 
37°C, the reaction was stopped by addition of 10 ~tl of glacial acetic 
acid. The mixture was lyophilized and taken up in the HPLC elution 
buffer. The radioactive substrate and product were separated by re- 
verse-phase HPLC with a Nucleosil 5Cxs column (150 ×4.6 mm) as 
stationary phase, and isocratic elution at a flow rate of 0.5 ml rain -1 
with 50 mM ammonium formate buffer, pH 3.9. Detection and quan- 
tification were performed with an LB 506 C-1 HPLC radioactivity 
monitor (Berthold, Bald Wildbald, Germany) using the Quickszint 
Flow 2 scintillator (Zinsser Analytic, Maidenhead, UK) at 0.5 ml 
min -1. For IC~0 determinations, the concentrations of the amino 
acids were 0.8 5 mM for 8 and 0.5-3 mM for 10; values+ standard 
deviations at 95% of confidence were calculated from the fitted regres- 
sion equations [19] using the logit-log plot. 
3. Results 
The A2pm analogues 2-10 studied in this work are listed in 
Fig. 1. It is noteworthy that in all cases but 9 and 10, the 
stereochemistry of the asymmetric carbon atoms was defined. 
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Fig. 1. Formulae of diaminopimelic a id and of its analogues. 
Moreover, for lanthionine derivatives 2-4 and phosphonic 
analogue 5, all the possible stereoisomers were available (ex- 
cept for meso-lanthionine sulfoxide 3a, which was presumably 
an optically inactive mixture of two isomers at the sulfur atom 
[11]). 
We first determined whether these compounds were sub- 
strates, at 10 mM, for the meso-A2pm-adding enzyme from 
E. coli (Table 1). UDP-MurNAc-L-Ala-D-[14C]Glu was used 
for this purpose. Owing to the difference in isoelectric point 
between the radioactive substrate and the putative product, 
high-voltage lectrophoresis was used for their separation. 
In a previous work [15], we had shown that the meso (2a) 
and LL (2e) isomers of lanthionine were substrates, the former 
being a much better one than the latter. (Because of priority 
rules in the R/S nomenclature system, LL-lanthionine has in 
fact a 2R,6R configuration.) Here, it appeared that the DD 
isomer 2h was also a substrate; the specific enzyme activity 
observed (1.0%) was approximately the same as with the LL 
isomer (1.3%). The addition of one oxygen atom to the sulfur 
(lanthionine sulfoxide 3) moderately reduced the specific ac- 
tivity, whereas that of two oxygen atoms (lanthionine sulfone 
4) decreased it to a great extent. In each ease, the meso isomer 
(3a, 4a) was a much better substrate than the LL (3e, 4c) or 
DD (3h, 4b) isomer. 
No stereoisomers of the phosphonic analogue 5 were sub- 
strates, even at high enzyme concentration. This agreed with 
the result previously obtained with the unresolved mixture of 
the four isomers [14]. 
Heterocyclic, conformationally constrained analogues 6 
(imidazole) and 7 (isoxazoline) were poor substrates; only 
with the 2S,5'R isomer 7a was non-negligible activity ob- 
served (5.2%). 
Fluorinated analogue 8 [(2S,3R,6S)-3-fluoro-A2pm] was the 
best substrate found in this study (spec. act. 55%). 4-Methyl- 
ene-A2pm 9 and N-hydroxy-A2pm 10 were also substrates 
with lower specific activities (1.4 and 16%, respectively); since 
these compounds were mixtures of 3 and 4 stereoisomers, 
respectively, it is conceivable that one stereoisomer was a 
better substrate than the others. 
The Km values of MurE for the best substrates were deter- 
mined: 3.5+0.8 and 9.2+ 1.2 mM for 8 and 10, respectively. 
These values are to be compared with those previously found 
for meso-A2pm la, LL-A2pm lb and meso-lanthionine 2a: 
0.04, 36 and 1.5 mM, respectively [15,17]. MurE did not fol- 
low simple kinetics with the fairly good substrate 3a: v vs. 
log[S] plots were bell-shaped with the top near 10 mM (not 
shown). This kind of curve is obtained in the case of excess 
substrate inhibition [20,21]. Owing to the marked effect of this 
phenomenon, o Km value could be calculated. 
Compounds were also assayed, at 5 mM, for the inhibition 
of the addition of meso-[14C]A2pm to UDP-MurNAc-dipep- 
tide (Table 1). The radioactive substrate and product were 
separated by reverse-phase HPLC and quantitated by on- 
line scintillation counting, as already described for the L-ala- 
nine-adding and D-glutamate-adding enzymes [22,23]. Gener- 
ally, the greatest extents of inhibition were observed with the 
best substrates: this presumably reflected the fact that these 
compounds behaved as competitive substrates. IC50 values for 
the most potent inhibitors were determined: 2.3 +0.2 and 
0.56 + 0.06 mM for 8 and 10, respectively. The stereoisomers 
of phosphonic analogue 5, which were not substrates, dis- 
played moderate inhibition (approx. 35% for 5e and 5d). 
Here again, this was consistent with our previous result ob- 
tained with the mixture of the four stereoisomers (50% inhibi- 
tion at 10 rnM) [14]. 
Table 1 
Effects of the Aepm analogues on the meso-A2pm-adding activity 
Compound Specific activity a (%) Inhibition b (%) 
2a 52 c n.d. d 
2b 1.0-+0.1 20_+4 
2c 1.3 -+ O. 1 n.i. e 
3a 34_ +1 14_+4 
3b 0.36 _+ 0.20 n.i. 
3c 0.36 _+ 0.03 n.i. 
4a 1.12 _+ 0.01 n.i. 
4b 0.20 + 0.02 n.i. 
4e 0.20 _+ 0.05 n.i. 
5a n.p/ 9 + 3 
5b n.p. 20 _+ 5 
5e n.p. 34 _+ 2 
5d n.p. 35 + 2 
6 0.10_+0.02 n.i. 
7a 5.2 _+ 1.0 n.i. 
7b 1.0 -+ 0.3 n.i. 
8 55_+3 68+1 
9 1.4-+0.1 10+2 
10 16+ 1 90-+ 1 
~Substrate activity at 10 mM, calculated relative to that obtained with 
meso-A2pm at the same concentration [100% = 33 + 1 nmol min -1 (mg 
protein)-1]. Mean + S.D. of two determinations. 
blOo(1--vi/Vo), where Vo is the uninhibited velocity and vi the velocity 
at 5 mM compound. Mean _+ S.D. of three determinations. 
°Taken from [15]. 
dn.d., not determined. 
en.i., no inhibition at 5 mM compound. 
fn.p., no product formation after 60 min with 6.3 }.tg of protein. 
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Fig. 2. The diaminopimelate pathway. 
4. Discussion 
The results obtained with lanthionine and derivatives there- 
of show that the specificity of MurE towards these substrates 
varies in the order: lanthionine>lanthionine sulfoxide>> 
lanthionine sulfone. Moreover, for each compound, the spe- 
cificity for the stereoisomers can be described as: me- 
so>>DD~LL.  As far as the DD and LL isomers are 
concerned, this result is somewhat different from that found 
with A2pm, where the specific activity with the DD isomer lc 
is 2.6-fold higher than with the LL isomer lb [15]. This would 
mean a stricter stereospecificity towards the distal recognition 
site of A2pm (the one which carries the nonreacting amino 
group) than towards the proximal recognition site (the one 
which participates in the formation of the peptide bond). 
When considering the substrate assays only, this rule does 
not seem to apply to lanthionine and its derivatives. However, 
the fact that DD-lanthionine 3b inhibits the incorporation of 
meso-[14C]A2pm whereas LL-lanthionine 3e does not suggests 
that the affinity of the enzyme for 3b is greater than that for 
3c. 
It is noteworthy that the order lanthionine > lanthionine 
sulfoxide > lanthionine sulfone, on the one hand, and the or- 
der meso > LL= DD, on the other, were also found when 
considering the specific activities of A2pm dehydrogenase 
173 
from Bacillus sphaericus and DapF from 17,. coli [5]. However, 
these in vitro effects were not translated into conspicuous 
antibacterial effects: none of the isomers of 3 or 4 caused 
any inhibition of growth when tested against a series of or- 
ganisms on defined media on plates; only 4c inhibited slightly 
B. subtilis growth at high doses (->350 p,g per test disc) [11]. 
On the other hand, it was shown that A2pm auxotrophs could 
grow, in the presence of lysine, with exogenous lanthionine 
([15], and references therein), the meso isomer of the sulfur 
amino acid being incorporated into peptidoglycan [15]. Such a 
result illustrates the fact that certain A2pm analogues can 
totally replace A2pm in peptidoglycan without affecting cell 
viability. 
Substrate analogues in which a phosphonic acid moiety 
replaces a carboxyl group have often proven to be good en- 
zyme ligands. This does not hold true for MurE, since mono- 
phosphonate compounds 5 are not substrates and are only 
weak inhibitors; moreover, the biphosphonate analogue 
(1,5-diaminopentane-l,5-diyl)diphosphonic acid (mixture of 
isomers) does not inhibit the enzyme at all [14]. Nevertheless, 
one can notice that, from a stereochemical point of view, the 
poorest inhibitor 5a corresponds to LL-A2pm (51t correspond- 
ing to Do-A2pm, and 5b and 5c to meso-A~pm): this may be 
another indication of the stricter stereochemical requirements 
of the distal recognition site. We previously showed [9] that 
the isomers of 5 were generally weak competitive inhibitors 
(millimolar ange) of A2pm decarboxylase from wheat germ 
Triticum vulgaris (which has the same properties as bacterial 
LysA), A2pm dehydrogenase from B. sphaericus, and DapF 
from E. coli. Compound 5b inhibited the growth of Salmonel- 
la typhimurium LT-2 (MIC, 1 gg ml-1), and a tripeptide con- 
taining 5a was active against E. coli and Citrobacter freundii 
(MIC range, 4-32 gg ml-1). These effects were reversed by LL- 
A2pm or meso-A2pm, indicating that the target was A2pm 
metabolism. However, owing to the very weak inhibitory po- 
tency of 5b and 5a towards MurE, the involvement of MurE 
inhibition in the antibacterial effects is unlikely. 
Heterocyclic analogues 6 and 7 are poor substrates for 
MurE. They were shown to be devoid of inhibitory activity 
towards DapF or A2pm dehydrogenase, except isoxazoline 7b, 
which was a good inhibitor of the latter enzyme [8]. Its anti- 
bacterial effect against B. sphaericus [8] can therefore be as- 
cribed to the inhibition of A2pm dehydrogenase, this organ- 
ism being dependent on this activity for the synthesis of meso- 
A2pm. 
The fact that fluorinated analogue 8 is a good substrate for 
the enzyme is not surprising, since it stereochemically corre- 
sponds to meso-A2pm. Unfortunately, the other isomers of 3- 
fluoro-A2pm [6] could not be tested, having decomposed upon 
storage. Compound 8 was shown to be a good competitive 
inhibitor of DapF and to undergo a rapid epimerase-catalyzed 
elimination of hydrogen fluoride; however, it was devoid of 
antibacterial ctivity, except against B. megaterium (50% in- 
hibition at 100 gg m1-1) [6]. 
N-Hydroxy-Azpm 10 is the most interesting compound of 
this study since it is active on the four enzymes MurE, DapF, 
LysA and A2pm dehydrogenase. It functions as an alternative 
substrate for MurE and strongly inhibits the incorporation of 
meso-[14C]Azpm. Assuming that the inhibition is competitive, 
the ICs0 value of 0.56 mM would correspond to a Ki value of 
0.4 mM according to the Cheng-Prusoff equation [24]. Since 
the Km value found is 9.2 mM, one can suppose that certain 
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stereoisomers are good inhibitors without being substrates. In 
this regard, the synthesis of stereochemically defined N-hydro- 
xy analogues would be of great interest. Previously, we 
showed that the mixture of isomers 10 was an alternative 
substrate for A2pm dehydrogenase from B. sphaericus (22% 
velocity relative to meso-A2pm), a moderate inhibitor of LysA 
from B. sphaericus (Ki = 0,91 mM) and a very potent inhibitor 
of DapF from E. coli (Ki =5.6 ~tM); it inhibited by 75% the 
growth of B. megaterium at 20 ~g m1-1, and totally that of 
B. subtilis at 500 p.g m1-1 [5,11]. 
The case of 4-methylene-Azpm 9 deserves pecial comment. 
First synthesized by the Delalande group [10], and then by 
ourselves [5], it was shown to be a weak inhibitor of E. coli 
LysA (30% inhibition at 10 mM) and a noncompetitive inhi- 
bitor of E. coli DapF (Ki =0.95 mM) [5,10]. Interestingly, it 
displayed substantial antibacterial ctivity against Gram-ne- 
gative species in defined minimal media [10], but not in com- 
plex media [5]. Moreover, it was capable of restoring the 
growth of an A2pm and lysine auxotroph in the presence of 
lysine [10]. Although a poor substrate for MurE, 9 is therefore 
incorporated into UDP-MurNAc-tripeptide and peptidogly- 
can in vivo; this is another example of the replacement of 
A2pm by an analogue in peptidoglycan. The antibacterial ef- 
fect observed in minimal media probably reflects a depletion 
of intracellular lysine, as indicated by its reversal upon L-ly- 
sine supplementation [10]. 
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